FDA Raises Concerns About China-Developed Drugs – The Wall Street Journal

U.S. regulators are poised to tap the brakes on approving dozens of cancer drugs and other new medicines developed in China.

The regulators have expressed concerns about the quality of studies largely conducted in China and whether the results can apply to patients in the U.S.

Leave a comment

Your email address will not be published. Required fields are marked *